StreetInsider.com News Articles

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

CAMBRIDGE, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in September:

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Editas Medicine to Participate in Upcoming Investor Conferences

Tue, 01 Sep 2026 09:00:00 -0400

Wells Fargo Healthcare Conference
Format: Fireside Chat
Date: Tuesday, September 8
Time: 4:30 p.m. ET
Location: Boston, MA

2026 Cantor Global Healthcare Conference
Format: Fireside Chat
Date: Thursday, September 10
Time: 3:55 p.m. ET
Location: New York, NY

To access the live webcast of Editas Medicine’s Fireside

Ladenburg Thalmann Starts Editas Medicine (EDIT) at Buy

Tue, 18 Aug 2026 06:35:02 -0400

Ladenburg Thalmann initiates coverage on Editas Medicine (NASDAQ: EDIT) with a Buy rating and a price target of $6.00.

For an analyst ratings summary and ratings history on Editas Medicine click here. For more ratings news on Editas Medicine click here.

Shares of Editas Medicine closed at $2.84 yesterday.

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form SCHEDULE 13G Editas Medicine, Inc. Filed by: ADAR1 Capital Management, LLC

Fri, 14 Aug 2026 21:30:00 -0400

si-local-file:///var/storage/secattach/20260814/26933321.html

Form 3 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892200.html

Form 3 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892200.html

Form 4 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892206.html

Form 4 Editas Medicine, Inc. For: Aug 06 Filed by: Ellinor Patrick Thomas II

Fri, 07 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260807/26892206.html

Editas Medicine (EDIT) Tops Q2 EPS by 12c

Wed, 05 Aug 2026 16:45:37 -0400

Editas Medicine (NASDAQ: EDIT) reported Q2 EPS of ($0.15), $0.12 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $11.89 million.

For earnings history and earnings-related data on Editas Medicine (EDIT) click here.

Form 4 Editas Medicine, Inc. For: Aug 03 Filed by: Parison Amy

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874176.html

Form 4 Editas Medicine, Inc. For: Aug 03 Filed by: Parison Amy

Wed, 05 Aug 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260805/26874176.html

Form 10-Q Editas Medicine, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873964.html

Form 10-Q Editas Medicine, Inc. For: Jun 30

Wed, 05 Aug 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260805/26873964.html

Form 8-K Editas Medicine, Inc. For: Aug 03

Wed, 05 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26873704.html

Form 8-K Editas Medicine, Inc. For: Aug 03

Wed, 05 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260805/26873704.html

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Wed, 05 Aug 2026 16:01:00 -0400

EDIT-401 on track for CTN submission this month with data update in Q1 2027

Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates

Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028

CAMBRIDGE, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today reported financial results for the

Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Wed, 05 Aug 2026 16:01:00 -0400

EDIT-401 on track for CTN submission this month with data update in Q1 2027

Recently presented pre-clinical data demonstrating ~90% or greater mean reduction in multiple atherogenic lipoproteins, including LDL-C, Lp(a) and ApoB with EDIT-401 in non-human primates

Recent financing strengthens Company’s capital position, supporting continued advancement of EDIT-401 program, with cash runway into the second half of 2028

Editas Medicine adds cardiovascular geneticist to its board

Tue, 04 Aug 2026 16:15:46 -0400

Editas Medicine (Nasdaq: EDIT) appointed Patrick T. Ellinor, M.D., Ph.D., to its board of directors, effective August 6, 2026, according to a press release from the Cambridge, Mass.-based gene editing company.

Dr. Ellinor serves as Executive Director of the Heart and Vascular Institute at Mass General Brigham and as Director of the Cardiovascular Disease Initiative at the Broad Institute of MIT and Harvard. He also holds a professorship at Harvard Medical School.

His research has focused on the genetics of cardiovascular disease, including genetic analyses of atrial fibrillation, with work spanning human genetics, genomics, computational biology, and artificial intelligence.

Editas board chair Jessica

Editas Medicine adds cardiovascular geneticist to its board

Tue, 04 Aug 2026 16:15:46 -0400

Editas board chair Jessica

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

Tue, 04 Aug 2026 16:15:00 -0400

Recognized leader in cardiovascular medicine and human genetics brings extensive experience spanning scientific innovation, therapeutic discovery, and clinical leadership as Editas advances EDIT-401 to the clinic

CAMBRIDGE, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced the appointment of Patrick T. Ellinor, M.D., Ph.D., to its Board of Directors, effective August 6, 2026. The Company also announced that Elliott Levy, M.D., will step down from the Board and his role as an independent director.

Dr. Ellinor has dedicated

Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.

Tue, 04 Aug 2026 16:15:00 -0400

Form 4 Editas Medicine, Inc. For: Jul 28 Filed by: Burkly Linda

Wed, 29 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260729/26836123.html

Form 4 Editas Medicine, Inc. For: Jul 28 Filed by: Burkly Linda

Wed, 29 Jul 2026 16:51:00 -0400

si-local-file:///var/storage/secattach/20260729/26836123.html

Form SCHEDULE 13G/A Editas Medicine, Inc. Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:20:00 -0400

si-local-file:///var/storage/secattach/20260729/26834262.html